Invenomic Capital Management LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001769456
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 116 positions · Total reported value $1.67B · Top-10 concentration 29.2% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 66.9% · 35 new · 31 cut · 35 exited
Active Share (vs S&P 500): 99.0% · vs QQQ: 99.1% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): +2.7% · vs SPY +0.6% · Prev Value $1.67B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +8.2% · vs SPY +6.1% · Latest Value $2.02B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2026 13F filing, Invenomic Capital Management LP disclosed 116 equity positions with a combined reported value of $1.67B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 29.2% of reported value. HoldingsHub classifies the profile as Mid / High Turnover.
The largest disclosed positions as of Q2 2026 were GPN ($63.97M), UHS ($63.53M), WDAY ($58.28M). By sector, the heaviest allocations are Technology 28.2%, Consumer Discretionary 25.2%. Versus the prior quarter, allocation shifted toward Communication Services (+3.3pp), Technology (+2.6pp) and away from Industrials (-1.2pp), Other (-2.0pp).
Versus the prior quarter, Invenomic Capital Management LP opened 35 new positions, trimmed 31 and fully exited 35, a turnover rate of 66.9% of positions. The portfolio's overlap with the prior quarter was 56% of names.
The largest new positions opened in Q2 2026 were BDX ($41.34M), CHTR ($40.16M), INTU ($27.82M).
Of the 35 positions fully exited versus the prior quarter, the largest were CHRD ($73.23M), TFX ($52.16M), AKAM ($46.59M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Fully Exited (vs previous quarter)
- CHRD CHORD ENERGY CORPORATION · prev qtr: $73.23M
- TFX TELEFLEX INCORPORATED · prev qtr: $52.16M
- AKAM AKAMAI TECHNOLOGIES INC · prev qtr: $46.59M
- RNG RINGCENTRAL INC · prev qtr: $30.21M
- ACHC ACADIA HEALTHCARE COMPANY IN · prev qtr: $27.65M
- RAMP LIVERAMP HLDGS INC · prev qtr: $26.82M
- SOLV SOLVENTUM CORP · prev qtr: $26.20M
- SNAP SNAP INC · prev qtr: $24.20M
Insider Transactions (Form 4)
Latest Invenomic Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Invenomic Capital Management LP is an SEC-registered 13F filer based in Boston, MA, United States. As of Q3 2026 it reported 116 US equity positions with a combined value of $2.02B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-110459 (status: Approved), registered 2017-04-20
- Regulatory AUM (Form ADV): $3.39B as of 2026-03-31
- Client mix (by RAUM): registered investment companies 60%, pension and profit-sharing plans 40%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 116 positions · $2.02B reported value (Q3 2026)
- Top 10 holdings = 29.4% of reported value
- Largest position: UHS (UNIVERSAL HLTH SVCS INC) at 3.9%
- Average position size: $17.43M
Sector Tilt
- Consumer Discretionary 28.5%
- Information Technology 26.1%
- Industrials 14.9%
- (classified holdings cover 98% of value)
Quarterly Activity
- Q3 2026: 35 new, 45 added, 31 reduced, 35 exited
- 5 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
881.58K | $63.97M | 3.82% | Reduce | |
| 2 |
|
427.26K | $63.53M | 3.79% | Add | |
| 3 |
|
476.11K | $58.28M | 3.48% | Reduce | |
| 4 |
|
4.91M | $52.09M | 3.11% | Add | |
| 5 |
|
869.41K | $49.70M | 2.97% | Add | |
| 6 |
|
575.35K | $42.73M | 2.55% | Reduce | |
| 7 |
|
273.18K | $41.34M | 2.47% | New | |
| 8 |
|
1.06M | $41.24M | 2.46% | Add | |
| 9 |
|
282.42K | $40.16M | 2.40% | New | |
| 10 |
|
1.16M | $36.00M | 2.15% | Reduce | |
| 11 |
|
479.22K | $34.90M | 2.08% | Add | |
| 12 |
|
2.35M | $34.33M | 2.05% | Reduce | |
| 13 |
|
908.77K | $32.86M | 1.96% | Reduce | |
| 14 |
|
14.26M | $30.80M | 1.84% | Add | |
| 15 |
|
193.30K | $30.28M | 1.81% | Reduce | |
| 16 |
|
1.08M | $29.56M | 1.76% | Reduce | |
| 17 |
|
106.61K | $27.82M | 1.66% | New | |
| 18 |
|
1.74M | $27.61M | 1.65% | Reduce | |
| 19 |
|
842.16K | $27.56M | 1.65% | Reduce | |
| 20 |
|
160.64K | $25.53M | 1.52% | Reduce | |
| 21 |
|
520.24K | $25.52M | 1.52% | Reduce | |
| 22 |
|
438.22K | $24.69M | 1.48% | Hold | |
| 23 |
|
532.08K | $23.54M | 1.41% | Reduce | |
| 24 |
|
2.09M | $22.91M | 1.37% | Add | |
| 25 |
|
470.22K | $22.45M | 1.34% | Reduce | |
| 26 |
|
290.71K | $21.04M | 1.26% | Add | |
| 27 |
|
220.49K | $20.88M | 1.25% | Reduce | |
| 28 |
|
2.41M | $20.12M | 1.20% | Add | |
| 29 |
|
220.07K | $19.84M | 1.19% | New | |
| 30 |
|
1.43M | $19.63M | 1.17% | Reduce | |
| 31 |
|
1.79M | $19.43M | 1.16% | Add | |
| 32 |
|
892.66K | $19.03M | 1.14% | Reduce | |
| 33 |
|
1.40M | $18.13M | 1.08% | Add | |
| 34 |
|
511.24K | $17.17M | 1.02% | New | |
| 35 |
|
2.68M | $16.41M | 0.98% | Reduce | |
| 36 |
|
216.22K | $16.22M | 0.97% | Reduce | |
| 37 |
|
772.03K | $15.98M | 0.95% | Reduce | |
| 38 |
|
182.39K | $15.97M | 0.95% | Reduce | |
| 39 |
|
2.80M | $15.78M | 0.94% | Reduce | |
| 40 |
|
738.50K | $15.77M | 0.94% | Reduce | |
| 41 |
|
629.81K | $15.46M | 0.92% | Add | |
| 42 |
|
178.69K | $15.38M | 0.92% | Add | |
| 43 |
|
610.31K | $15.19M | 0.91% | Add | |
| 44 |
|
233.03K | $14.92M | 0.89% | New | |
| 45 |
|
135.38K | $14.61M | 0.87% | Add | |
| 46 |
|
369.48K | $12.76M | 0.76% | New | |
| 47 |
|
508.05K | $12.50M | 0.75% | Reduce | |
| 48 |
|
613.97K | $12.06M | 0.72% | New | |
| 49 |
|
233.91K | $11.97M | 0.71% | Add | |
| 50 |
|
152.33K | $11.92M | 0.71% | New | |
FAQ
What did Invenomic Capital Management LP buy in 2026-Q2?
In its 2026-Q2 13F filing, Invenomic Capital Management LP reported 116 equity positions worth $1.67B in aggregate; its largest disclosed positions were GPN ($63.97M), UHS ($63.53M), WDAY ($58.28M).
How large is Invenomic Capital Management LP's portfolio?
Invenomic Capital Management LP reported $1.67B of long equity holdings across 116 positions as of 2026-Q2. Top-10 holdings account for 29.2% of reported value.
What is Invenomic Capital Management LP's investment style?
HoldingsHub classifies the portfolio as Mid / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.